Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

Related Issuers

FINAL TERMS: Neopharmed E750m sr sec 2-part, $400m 6NC1 FRN E+425bp at 99.50; E350m 6NC2 fixed-rate 7.125% at par

HYC US Market: Deal Flow - GeneralHYC European Market: Deal Flow - General

Neopharmed Gentili SpA (NEGENT) EUR750m144A/Reg S fixed/floating sr sec notes 2-part. B3/B/B+ (stable/sable/stable). Via BNP (B&D)/GS jt physical books/IMI jt glocos/Banca Akros/CA/JPM/Natixis jt books. No reg rights. List Lux. NY law. Settles 04/08.

- EUR400m (from expect EUR375m,  and EUR300m minimum) sr sec FRN due 2030 (6y). NC1 (MWC B+50bp), then at 101, par. IPT: E+450bp, 0%, 99.00-99.50. Px talk: E+425-450bp, 0%, 99.50. Final terms: EUR400m at E+425bp, 0% floor, at 99.50.

- EUR350m (from expected EUR375m, and EUR300m minimum) sr sec fixed-rate notes due 2030 (6y). NC2 (MWC B+50bp) (50%,25%,par). Equity claw: 2y 40%. Special call: 10% per year the first 2 years at 103. IPT: low-mid 7s. Px talk: 7.00%-7.25%. Final terms: EUR350m 7.125% at par.

Did investor call at 11am UKT 03/25, Q&A sessions 03/25-27. Books closed at 12pm UKT today. Reconfirms due 2:30pm UKT today. Pricing today UK afternoon. UOP: repay the existing EUR700m unitranche notes, and EUR26m for cash on the B/S. Equity sponsors: Ardian and NB Renaissance. Biz: a leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products. HQ: Milan, Italy.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.